RxDoctor Payments Data

Ryan Tomlinson, MD

Internal Medicine · Des Moines, IANPI 1497054662

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,622 of the $1,921 with a category attached, or 84.4%. Pfizer accounts for 94.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,823 and has fallen 99.0% since, to $18 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,921in general payments, 2019–2025

Across 9 payments — averaging $213.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Medtronic$29
  • Johnson & Johnson$26
  • Digital Diagnostics Inc.$25
  • Abbott$18
$206,918in research payments, 2019–2025

Across 62 payments — averaging $3337.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$207K

What the payments were for

  • Travel & lodging$1,62284%
  • Food & beverage$30016%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$1,823
Medtronic1$29
Johnson & Johnson2$26
Digital Diagnostics Inc.1$25
Abbott1$18

How this compares

$1,921 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$124,099
Medicare patients
257
Services billed
2,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$67,516
EliquisApixaban47$36,313
XareltoRivaroxaban39$29,873
OzempicSemaglutide13$20,977
JanuviaSitagliptin Phosphate25$17,100
MounjaroTirzepatide16$16,330
Bydureon BciseExenatide Microspheres11$8,515
MyrbetriqMirabegron12$5,473
MovantikNaloxegol Oxalate11$5,379
ConcertaMethylphenidate Hcl11$4,532
Incruse ElliptaUmeclidinium Bromide11$4,104
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$2,494
Omeprazole146$2,377
Novolog FlexpenInsulin Aspart18$2,361
Atorvastatin Calcium229$2,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,823$36,31347 claims
Johnson & JohnsonXarelto, Concerta$26$34,40450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →